Pfizer has introduced Rimegepant ODT in India for the acute treatment of migraine, with or without aura, specifically for adults who have not responded adequately to triptan therapy. The new 75 mg orally disintegrating tablet offers rapid and long-lasting pain relief, with benefits extending up to 48 hours after administration. It is also not linked to medication overuse headaches, a concern commonly associated with many migraine therapies.
The convenient ODT formulation allows patients to take the medication without water, supporting quicker action and easier use during migraine onset. Beyond pain relief, the treatment provides sustained improvement in bothersome symptoms and supports early return to daily activities.
By targeting the calcitonin gene-related peptide (CGRP) pathway—an important driver of migraine—Rimegepant establishes a new benchmark in comprehensive migraine management in India. Its favorable safety profile and fast onset enable patients to regain functionality sooner, marking a significant advancement in migraine care.
Also Read
